<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1">
<!-- Latest compiled and minified CSS -->
<link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.4/css/bootstrap.min.css">
<!-- Optional theme -->
<link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.4/css/bootstrap-theme.min.css">
<!-- Latest compiled and minified JavaScript -->
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.4/js/bootstrap.min.js"></script>
<style>img { width: 150px; height: auto; }</style>
</head>
<body role="document">
<div class="container theme-showcase" role="main">
<h3>FDA modifies partial clinical hold on Tekmira Ebola study</h3>
<table class="table table-striped"><tr><td>1</td><td>The company's application to study the treatment, TKM-Ebola, remains on partial clinical hold for doses above 0.24 mg/kg per day, Tekmira said on Friday.</td></tr>
<tr><td>2</td><td>The FDA placed Tekmira's early-stage study on a clinical hold in July, asking the company for data on how the therapy works and requesting a change to design of the study related to multiple dosing.</td></tr>
<tr><td>3</td><td>The clinical hold was modified in August into a partial hold asking only for a change in the study design.</td></tr>
<tr><td>4</td><td>Tekmira had reported interim results in May showing that a higher dose of 0.30 mg/kg per day was well-tolerated.</td></tr>
<tr><td>5</td><td>Tekmira said it plans to resume the early study in the coming weeks, and expects results from the study in the second half of 2015.</td></tr>
<tr><td>6</td><td>Tekmira shares rose about 2 percent to $17.95 following the lifting of a trading halt imposed at 8.30 a.m. ET.</td></tr>
</table></body></div></html>